Targeted therapies induced depigmentation: a review
Skin depigmentation or vitiligo-like depigmentation (VLD) is one of the most prevalent cutaneous adverse events during targeted therapies for cancers or autoimmune diseases. The depigmentation is usually with high mental burden and affect the disease treatment, some of which are even clinical marker...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1625738/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849243187692961792 |
|---|---|
| author | Zhaoyang Wang Zhaoyang Wang Meng Wang Meng Wang Tianyu Wang Tianyu Wang Xiaoxiao Yan Xiaoxiao Yan Zhenhua Yue Zhenhua Yue Yonghu Sun Yonghu Sun |
| author_facet | Zhaoyang Wang Zhaoyang Wang Meng Wang Meng Wang Tianyu Wang Tianyu Wang Xiaoxiao Yan Xiaoxiao Yan Zhenhua Yue Zhenhua Yue Yonghu Sun Yonghu Sun |
| author_sort | Zhaoyang Wang |
| collection | DOAJ |
| description | Skin depigmentation or vitiligo-like depigmentation (VLD) is one of the most prevalent cutaneous adverse events during targeted therapies for cancers or autoimmune diseases. The depigmentation is usually with high mental burden and affect the disease treatment, some of which are even clinical markers for good prognosis. This study aimed to explore the underlying immunopathologic mechanisms of VLD induced by targeted therapy for cancer and autoimmune disease as well as vaccine, such as immune checkpoint inhibitors (e.g., programmed death 1/programmed death–ligand 1 and cytotoxic T-lymphocyte antigen-4 inhibitors), v-raf murine sarcoma viral oncogene homolog inhibitors, tyrosine kinase inhibitors, and other targeted agents. Additionally, it examined the clinical presentations, prognostic implications, and management strategies for VLD across oncologic and nononcologic contexts, including cases associated with vaccines and biologics. The development of VLD often correlates with improved therapeutic outcomes, but it presents unique challenges in balancing antitumor efficacy with patients’ quality of life. This review integrated insights from oncology, dermatology, and immunology, and underscored the need for multidisciplinary approaches to enhance the understanding, prevention, and management of these complex cutaneous adverse events. |
| format | Article |
| id | doaj-art-b9d37e0eef694057b42e493201e7c14f |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-b9d37e0eef694057b42e493201e7c14f2025-08-20T03:59:32ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-08-011610.3389/fimmu.2025.16257381625738Targeted therapies induced depigmentation: a reviewZhaoyang Wang0Zhaoyang Wang1Meng Wang2Meng Wang3Tianyu Wang4Tianyu Wang5Xiaoxiao Yan6Xiaoxiao Yan7Zhenhua Yue8Zhenhua Yue9Yonghu Sun10Yonghu Sun11Dermatology Hospital of Shandong First Medical University, Jinan, ChinaShandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, ChinaDermatology Hospital of Shandong First Medical University, Jinan, ChinaShandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, ChinaDermatology Hospital of Shandong First Medical University, Jinan, ChinaShandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, ChinaDermatology Hospital of Shandong First Medical University, Jinan, ChinaShandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, ChinaDermatology Hospital of Shandong First Medical University, Jinan, ChinaShandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, ChinaDermatology Hospital of Shandong First Medical University, Jinan, ChinaShandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, ChinaSkin depigmentation or vitiligo-like depigmentation (VLD) is one of the most prevalent cutaneous adverse events during targeted therapies for cancers or autoimmune diseases. The depigmentation is usually with high mental burden and affect the disease treatment, some of which are even clinical markers for good prognosis. This study aimed to explore the underlying immunopathologic mechanisms of VLD induced by targeted therapy for cancer and autoimmune disease as well as vaccine, such as immune checkpoint inhibitors (e.g., programmed death 1/programmed death–ligand 1 and cytotoxic T-lymphocyte antigen-4 inhibitors), v-raf murine sarcoma viral oncogene homolog inhibitors, tyrosine kinase inhibitors, and other targeted agents. Additionally, it examined the clinical presentations, prognostic implications, and management strategies for VLD across oncologic and nononcologic contexts, including cases associated with vaccines and biologics. The development of VLD often correlates with improved therapeutic outcomes, but it presents unique challenges in balancing antitumor efficacy with patients’ quality of life. This review integrated insights from oncology, dermatology, and immunology, and underscored the need for multidisciplinary approaches to enhance the understanding, prevention, and management of these complex cutaneous adverse events.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1625738/fulltargeted drugsdepigmentationmelanocytesvaccineautoimmunityadverse drug reactions |
| spellingShingle | Zhaoyang Wang Zhaoyang Wang Meng Wang Meng Wang Tianyu Wang Tianyu Wang Xiaoxiao Yan Xiaoxiao Yan Zhenhua Yue Zhenhua Yue Yonghu Sun Yonghu Sun Targeted therapies induced depigmentation: a review Frontiers in Immunology targeted drugs depigmentation melanocytes vaccine autoimmunity adverse drug reactions |
| title | Targeted therapies induced depigmentation: a review |
| title_full | Targeted therapies induced depigmentation: a review |
| title_fullStr | Targeted therapies induced depigmentation: a review |
| title_full_unstemmed | Targeted therapies induced depigmentation: a review |
| title_short | Targeted therapies induced depigmentation: a review |
| title_sort | targeted therapies induced depigmentation a review |
| topic | targeted drugs depigmentation melanocytes vaccine autoimmunity adverse drug reactions |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1625738/full |
| work_keys_str_mv | AT zhaoyangwang targetedtherapiesinduceddepigmentationareview AT zhaoyangwang targetedtherapiesinduceddepigmentationareview AT mengwang targetedtherapiesinduceddepigmentationareview AT mengwang targetedtherapiesinduceddepigmentationareview AT tianyuwang targetedtherapiesinduceddepigmentationareview AT tianyuwang targetedtherapiesinduceddepigmentationareview AT xiaoxiaoyan targetedtherapiesinduceddepigmentationareview AT xiaoxiaoyan targetedtherapiesinduceddepigmentationareview AT zhenhuayue targetedtherapiesinduceddepigmentationareview AT zhenhuayue targetedtherapiesinduceddepigmentationareview AT yonghusun targetedtherapiesinduceddepigmentationareview AT yonghusun targetedtherapiesinduceddepigmentationareview |